HeartBeam (NASDAQ:BEAT – Get Free Report) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $0.1470 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.
HeartBeam (NASDAQ:BEAT – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. On average, analysts expect HeartBeam to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
HeartBeam Trading Up 7.0%
NASDAQ BEAT opened at $0.59 on Wednesday. The company has a fifty day simple moving average of $0.65 and a 200 day simple moving average of $1.00. HeartBeam has a 12-month low of $0.48 and a 12-month high of $4.00. The company has a market cap of $32.59 million, a P/E ratio of -1.05 and a beta of -0.78.
Institutional Trading of HeartBeam
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the stock. HC Wainwright dropped their price objective on shares of HeartBeam from $5.50 to $2.50 and set a “buy” rating on the stock in a research note on Friday, May 22nd. Wall Street Zen raised shares of HeartBeam from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Maxim Group initiated coverage on shares of HeartBeam in a report on Tuesday, July 14th. They issued a “buy” rating and a $2.00 target price on the stock. D. Boral Capital cut shares of HeartBeam from a “buy” rating to a “hold” rating in a research report on Monday, April 20th. Finally, Benchmark cut their price target on HeartBeam from $8.00 to $5.00 and set a “speculative buy” rating for the company in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, HeartBeam presently has a consensus rating of “Moderate Buy” and an average price target of $4.00.
Check Out Our Latest Research Report on BEAT
About HeartBeam
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.
Featured Stories
- Five stocks we like better than HeartBeam
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for HeartBeam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartBeam and related companies with MarketBeat.com's FREE daily email newsletter.
